



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 1 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 1. Identification

GHS product identifier : Milrinone Lactate Injection

Other means of identification : Milrinone Lactate Injection

Product type : Liquid.

Relevant identified uses of the substance or mixture and uses advised against

Product use : Pharmaceuticals (For intended use only).
Observe technical data sheet/instructions for use.
Specific Treatments: cardiac arrest or heart failure.

Area of application : Professional applications.

Supplier's details : Meitheal Pharmaceuticals, Inc.
8700 W. Bryn Mawr, Suite 600S
Chicago, IL 60631

Telephone: 224-443-4617
www.meithealpharma.com

e-mail address of person responsible for this SDS : info@meithealpharma.com

Emergency telephone number (with hours of operation) : 844-824-8426 (Monday - Friday, 08:00 - 18:00 CST)

Section 2. Hazards identification

OSHA/HCS status : While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

Classification of the substance or mixture : Not classified.

GHS label elements

Signal word : No signal word.

Hazard statements : No known significant effects or critical hazards.

Precautionary statements

Prevention : Not applicable.

Response : Not applicable.

Storage : Not applicable.

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 2 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 2. Hazards identification

Disposal : Not applicable.
Hazards not otherwise classified : None known.

Section 3. Composition/information on ingredients

Substance/mixture : Mixture
Other means of identification : Milrinone Lactate Injection

Ingredient name	Other names	%	CAS number
water	-	≥90	7732-18-5
glucose	-	≤5	50-99-7
milrinone	-	≤0.3	78415-72-2
l-(+)-lactic acid	-	≤0.3	79-33-4
sodium hydroxide	-	≤0.1	1310-73-2

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health and hence require reporting in this section.

Section 4. First aid measures

Description of necessary first aid measures

Eye contact : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.

Inhalation : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.

Skin contact : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.

Ingestion : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

Most important symptoms/effects, acute and delayed

Potential acute health effects

Eye contact : No known significant effects or critical hazards.
Inhalation : No known significant effects or critical hazards.
Skin contact : No known significant effects or critical hazards.
Ingestion : No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact : No specific data.

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 3 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 4. First aid measures

- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

Indication of immediate medical attention and special treatment needed, if necessary

- Notes to physician** : Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
- Specific treatments** : No specific treatment.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : Do not use water jet.

- Specific hazards arising from the chemical** : In a fire or if heated, a pressure increase will occur and the container may burst.

- Hazardous thermal decomposition products** : Decomposition products may include the following materials:
carbon dioxide
carbon monoxide

- Special protective actions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.
- For emergency responders** : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 4 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 6. Accidental release measures

Environmental precautions : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and materials for containment and cleaning up

Small spill : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill : Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

Section 7. Handling and storage

Precautions for safe handling

Protective measures : Put on appropriate personal protective equipment (see Section 8).

Advice on general occupational hygiene : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

Conditions for safe storage, including any incompatibilities : Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 5 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 8. Exposure controls/personal protection

Ingredient name	Exposure limits
water glucose milrinone l-(+)-lactic acid sodium hydroxide	None. None. None. None. ACGIH TLV (United States, 1/2021). C: 2 mg/m ³ NIOSH REL (United States, 10/2020). CEIL: 2 mg/m ³ OSHA PEL (United States, 5/2018). TWA: 2 mg/m ³ 8 hours.

Appropriate engineering controls

- : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Environmental exposure controls

- : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures

- : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

- : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection

- : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection

- : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

- : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

- : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 6 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 9. Physical and chemical properties

Appearance

Physical state	: Liquid. [Clear.]
Color	: Colorless to light yellow.
Odor	: Odorless.
Odor threshold	: Not available.
pH	: 3.2 to 4
Melting point	: Not applicable.
Boiling point	: Not applicable.
Flash point	: Not applicable.
Evaporation rate	: Not applicable.
Flammability (solid, gas)	: Not applicable.
Lower and upper explosive (flammable) limits	: Not applicable.
Vapor pressure	: Not applicable.
Vapor density	: Not available.
Relative density	: 1.018 [Water = 1]
Density	: 1.018 g/cm ³ [25°C (77°F)]
Solubility	: Soluble in the following materials: cold water and hot water.
Solubility in water	: Not available.
Partition coefficient: n-octanol/water	: Not applicable.
Auto-ignition temperature	: Not applicable.
Decomposition temperature	: Not applicable.
SADT	: Not available.
Viscosity	: Dynamic (room temperature): 0.9 mPa·s (0.9 cP) Kinematic (room temperature): Not applicable. Kinematic (40°C (104°F)): Not applicable.
Flow time (ISO 2431)	: Not available.

Section 10. Stability and reactivity

Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
Chemical stability	: The product is stable.
Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur. Under normal conditions of storage and use, hazardous polymerization will not occur.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 7 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 10. Stability and reactivity

Conditions to avoid : No specific data.

Incompatible materials : No specific data.

Hazardous decomposition products : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
glucose milrinone l-(+)-lactic acid	LD50 Oral	Rat	25800 mg/kg	-
	LD50 Oral	Rat	91 mg/kg	-
	LC50 Inhalation Dusts and mists	Rat - Male, Female	>7.94 mg/l	4 hours
	LD50 Dermal	Rabbit - Male, Female	>2000 mg/kg	-
	LD50 Oral	Rat - Female	3543 mg/kg	-

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
sodium hydroxide	Eyes - Mild irritant	Rabbit	-	400 ug	-
	Eyes - Severe irritant	Rabbit	-	24 hours 50 ug	-
	Eyes - Severe irritant	Rabbit	-	1 %	-
	Eyes - Severe irritant	Rabbit	-	0.5 minutes 1 mg	-
	Skin - Severe irritant	Rabbit	-	24 hours 500 mg	-

Sensitization

Not available.

Mutagenicity

Conclusion/Summary : Not available.

Carcinogenicity

Conclusion/Summary : Not available.

Reproductive toxicity

Conclusion/Summary : Not available.

Teratogenicity

Conclusion/Summary : Not available.

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 8 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 11. Toxicological information

Specific target organ toxicity (single exposure)

Name	Category	Route of exposure	Target organs
I-(+)-lactic acid	Category 3	-	Respiratory tract irritation
sodium hydroxide	Category 3	-	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on the likely routes of exposure : Not available.

Potential acute health effects

Eye contact : No known significant effects or critical hazards.
Inhalation : No known significant effects or critical hazards.
Skin contact : No known significant effects or critical hazards.
Ingestion : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.
Inhalation : No specific data.
Skin contact : No specific data.
Ingestion : No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate effects : Not available.
Potential delayed effects : Not available.

Long term exposure

Potential immediate effects : Not available.
Potential delayed effects : Not available.

Potential chronic health effects

Not available.

General : No known significant effects or critical hazards.

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 9 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 11. Toxicological information

Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Teratogenicity	: No known significant effects or critical hazards.
Developmental effects	: No known significant effects or critical hazards.
Fertility effects	: No known significant effects or critical hazards.

Numerical measures of toxicity

Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapors) (mg/l)	Inhalation (dusts and mists) (mg/l)
glucose	25800	N/A	N/A	N/A	N/A
milrinone	91	300	N/A	3	N/A
l-(+)-lactic acid	3543	2500	N/A	N/A	N/A

Section 12. Ecological information

Toxicity

Product/ingredient name	Result	Species	Exposure
l-(+)-lactic acid	Acute EC50 240000 µg/l Fresh water	Daphnia - Daphnia magna	48 hours
sodium hydroxide	Acute LC50 130 ppm Fresh water	Fish - Oncorhynchus mykiss	96 hours
	Acute EC50 40.38 mg/l Fresh water	Crustaceans - Ceriodaphnia dubia - Neonate	48 hours
	Acute LC50 125 ppm Fresh water	Fish - Gambusia affinis - Adult	96 hours

Conclusion/Summary : Not available.

Persistence and degradability

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
l-(+)-lactic acid	-	-	Readily

Bioaccumulative potential

Product/ingredient name	LogP _{ow}	BCF	Potential
water	-1.38	-	low
glucose	-3.24	-	low

Mobility in soil

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 10 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 12. Ecological information

Soil/water partition coefficient (K_{oc}) : Not available.

Other adverse effects : No known significant effects or critical hazards.

Section 13. Disposal considerations

Disposal methods : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information

	DOT Classification	IMDG	IATA
UN number	Not regulated.	Not regulated.	Not regulated.
UN proper shipping name	-	-	-
Transport hazard class(es)	-	-	-
Packing group	-	-	-
Environmental hazards	No.	No.	No.

Additional information

Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according to IMO instruments : Not available.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 11 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 15. Regulatory information

U.S. Federal regulations : TSCA 8(a) CDR Exempt/Partial exemption: Not determined
United States inventory (TSCA 8b): Not determined.
Clean Water Act (CWA) 311: sodium hydroxide

Clean Air Act Section 112 : Not listed

(b) Hazardous Air Pollutants (HAPs)

Clean Air Act Section 602 Class I Substances : Not listed

Clean Air Act Section 602 Class II Substances : Not listed

DEA List I Chemicals (Precursor Chemicals) : Not listed

DEA List II Chemicals (Essential Chemicals) : Not listed

SARA 302/304

Composition/information on ingredients

No products were found.

SARA 304 RQ : Not applicable.

SARA 311/312

Classification : Not applicable.

Composition/information on ingredients

Name	%	Classification
glucose	≤5	COMBUSTIBLE DUSTS
milrinone	≤0.3	ACUTE TOXICITY (oral) - Category 3 ACUTE TOXICITY (dermal) - Category 3 ACUTE TOXICITY (inhalation) - Category 3
I-(+)-lactic acid	≤0.3	SKIN IRRITATION - Category 2 SERIOUS EYE DAMAGE - Category 1 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3
sodium hydroxide	≤0.1	CORROSIVE TO METALS - Category 1 SKIN CORROSION - Category 1A SERIOUS EYE DAMAGE - Category 1 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3 HNO ₃ - Corrosive to digestive tract [severe]

SARA 313

Not applicable.

State regulations

Massachusetts : None of the components are listed.

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 12 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 15. Regulatory information

New York : None of the components are listed.

New Jersey : None of the components are listed.

Pennsylvania : None of the components are listed.

California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Section 16. Other information

Hazardous Material Information System (U.S.A.)

Health	/	0
Flammability		0
Physical hazards		0

Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

National Fire Protection Association (U.S.A.)



SDS Title: Milrinone Lactate Injection Safety Data Sheet	SDS Number: SDS-000022	Page Number: Page 13 of 13
Function: Regulatory Affairs	Effective Date: January 07, 2022	Version number: 2.0

Section 16. Other information

Reprinted with permission from NFPA 704, Identification of the Hazards of Materials for Emergency Response Copyright ©1997, National Fire Protection Association, Quincy, MA 02269. This reprinted material is not the complete and official position of the National Fire Protection Association, on the referenced subject which is represented only by the standard in its entirety.

Copyright ©2001, National Fire Protection Association, Quincy, MA 02269. This warning system is intended to be interpreted and applied only by properly trained individuals to identify fire, health and reactivity hazards of chemicals. The user is referred to certain limited number of chemicals with recommended classifications in NFPA 49 and NFPA 325, which would be used as a guideline only. Whether the chemicals are classified by NFPA or not, anyone using the 704 systems to classify chemicals does so at their own risk.

Procedure used to derive the classification

Classification	Justification
Not classified.	

History

Date of issue/Date of revision	: 01/07/2022
Date of previous issue	: 01/08/2020
Version	: 2.0
Prepared by	: Sphera Solutions
Key to abbreviations	: ATE = Acute Toxicity Estimate AMP = Acceptable maximum peak above the acceptable ceiling concentration for an 8-hr shift BCF = Bioconcentration Factor GHS = Globally Harmonized System of Classification and Labelling of Chemicals IATA = International Air Transport Association IBC = Intermediate Bulk Container IMDG = International Maritime Dangerous Goods LogPow = logarithm of the octanol/water partition coefficient MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution) N/A = Not available UN = United Nations
References	: HCS (U.S.A.)- Hazard Communication Standard International transport regulations

Indicates information that has changed from previously issued version.

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.